Showing 4971-4980 of 21485 results for "".
- Pediatric Anaphylaxis Model Flags Need for Repeat Epinephrinehttps://reachmd.com/news/pediatric-anaphylaxis-model-flags-need-for-repeat-epinephrine/2488117/Key Takeaways Among 2,318 children who received one epinephrine dose before ED arrival for an allergic reaction, 15.7% received epinephrine again after arriving at the ED or during subsequent inpatient care. Seven prehospital factors were significantly associated wit
- Stroke Admission Hyperglycemia Linked to Worse Discharge Functionhttps://reachmd.com/news/stroke-admission-hyperglycemia-linked-to-worse-discharge-function/2488100/Key Takeaways Among adults with acute ischemic stroke treated at a comprehensive stroke center in Al Ain, United Arab Emirates, admission hyperglycemia was common and was associated with worse discharge function. Algorithm-defined inappropriate inpatient glycemic man
- TLR4 Emerges in Gout Risk Link Between BMI and Pathogenesishttps://reachmd.com/news/tlr4-emerges-in-gout-risk-link-between-bmi-and-pathogenesis/2488096/Key Takeaways In U.S. National Health and Nutrition Examination Survey (NHANES) data from 9,700 adults, higher body mass index (BMI) was associated with higher gout odds in a dose-dependent pattern. Genetically inferred analyses also linked higher BMI to higher gout
- Plasma mNGS Q Fever Linked to Delayed Defervescencehttps://reachmd.com/news/plasma-mngs-q-fever-linked-to-delayed-defervescence/2488090/Key Takeaways At a single hospital in Changsha, China, a mostly acute 44-patient Q-fever cohort identified by plasma mNGS plus clinical criteria (41 acute, 3 chronic) was predominantly middle-aged and male; fever occurred in 95.5%, headache in 45.5%, and pulmonary involvement
- Small Fiber Neuropathy Diagnosis Didn't Change Pain Burdenhttps://reachmd.com/news/small-fiber-neuropathy-diagnosis-didnt-change-pain-burden/2488099/Key Takeaways In a Dutch tertiary-center SFN cohort followed for 3 to 6 months after diagnosis, pain intensity and EQ-5D-5L quality of life did not significantly change. Total societal costs and patient and family costs were statistically unchanged over follow-up; pr
- Three-Part Acne Scar Protocol Shows Progressive Changes Through 139 Dayshttps://reachmd.com/news/three-part-acne-scar-protocol-shows-progressive-changes-through-139-days/2488104/A multimodal protocol combining subcision, injectable treatment, and fractional laser therapy was associated with reductions in facial atrophic acne scar dimensions in a prospective case series published in Biomedicines. Ultrasound Tracks Changes Through 139 Days The stud
- Ovarian Cancer T-Cell-Macrophage States Track Chemo Responsehttps://reachmd.com/news/ovarian-cancer-t-cell-macrophage-states-track-chemo-response/2488075/Key Takeaways In a very small treatment-naive ovarian cancer cohort of fewer than 20 patients, predicted T-cell-macrophage doublets were dominated by CD8+ interactions and were relatively more enriched in chemotherapy-sensiti
- Lupus Nexus Builds a 3,500-Patient SLE Research Platformhttps://reachmd.com/news/lupus-nexus-builds-a-3500-patient-sle-research-platform/2488071/Key Takeaways Lupus Nexus integrates the prospective Lupus Landmark Study with a clinical coordinating center, biorepository, and DREAM data platform to link longitudinal clinical, patient-reported, biospecimen, and molecular data in systemic lupus erythematosus. As
- Dexmedetomidine Lowers Delirium After Hip Fracture Surgeryhttps://reachmd.com/news/dexmedetomidine-lowers-delirium-after-hip-fracture-surgery/2488070/Key Takeaways In a multicenter randomized trial of adults aged 65 to 90 years undergoing hip fracture surgery under spinal anesthesia with fascia iliaca block in China, postoperative delirium within 72 hours occurred less often with dexmedetomidine sedation than with propofol
- D-2570 Shows High PASI Response Rates in Phase 2 Psoriasis Studyhttps://reachmd.com/news/d-2570-shows-high-pasi-response-rates-in-phase-2-psoriasis-study/2488078/A novel oral TYK2 inhibitor produced significantly higher skin clearance rates than placebo in patients with moderate-to-severe plaque psoriasis, according to research published in Journal of the American Academy of Dermatology. D-2570 is a TYK2 inhibitor under development for aut